Why did maribavir fail in stem-cell transplants?

The Lancet Infectious Diseases

Volumn 11, Issue 4, 2011, Pages 255-257

  Snydman, David R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; GANCICLOVIR; PLACEBO; VALGANCICLOVIR;

CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DYSGEUSIA; HUMAN; LETTER; NAUSEA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBONUCLEOSIDES; STEM CELL TRANSPLANTATION; TRANSPLANTATION; TREATMENT FAILURE;

EID: 79953057416     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70033-0     Document Type: Letter

References (14)

1. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011, published online March 16. 10.1016/S1473-3099(11)70024-X.
2. Snydman DR Leflunomide: a small step forward in meeting the urgent need for treatment of drug resistant cytomegalovirus infection. Transplantation 2010, 90:362-363.
3. Avery RK Update on the management of ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect Dis 2008, 21:433-437.
4. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997, 90:2502-2508.
5. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.
6. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010, 12:489-496.
7. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997, 64:108-113.
8. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999, 13:797-804.
9. Guidance for industry: antiretroviral drugs using plasma RNA measurements-clinical considerations for accelerated and traditional approval 2002, 1-24. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services Food and Drug Administration, Silver Spring, (accessed Feb 2, 2011). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070968.pdf.
10. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998, 21:597-605.
11. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
12. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000, 181:717-720.
13. Stachel D, Kirby K, Corey L, Boeckh M CMV viral load as a predictor for transplant related mortality in the era of pre-emptive therapy. Bone Marrow Transplant 2008, 41:S1. S46 (abstr).
14. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263 Adis International Limited, (accessed Feb 2, 2011). http://www.ingentaconnect.com/content/adis/rdd/2007/00000008/00000003/art00006.